Patient, disease, and transplant characteristics
| . | Flu/Bu4 . | Flu/Bu4 + ATG . | Bu4/Cy . | Flu/Bu2 . | Flu/Bu2 + ATG . | Flu/Mel . | Flu/Mel + ATG . |
|---|---|---|---|---|---|---|---|
| Patients, n | 477 | 276 | 518 | 405 | 263 | 198 | 72 |
| Median age, y | 56 | 56 | 51 | 63 | 63 | 63 | 64 |
| Age, y | |||||||
| 18-39 | 72 (15) | 54 (20) | 113 (22) | 14 (4) | 13 (5) | 6 (3) | 6 (8) |
| 40-59 | 255 (54) | 130 (47) | 355 (68) | 112 (27) | 78 (30) | 52 (26) | 17 (24) |
| ≥60 | 150 (31) | 92 (33) | 50 (10) | 279 (69) | 172 (65) | 140 (71) | 49 (68) |
| Sex, male | 264 (55) | 156 (57) | 266 (51) | 257 (63) | 115 (58) | 157 (60) | 43 (60) |
| CMV serostatus | |||||||
| Negative | 179 (37) | 100 (36) | 211 (41) | 169 (42) | 53 (27) | 87 (33) | 17 (24) |
| Positive | 290 (61) | 173 (63) | 303 (58) | 234 (58) | 144 (73) | 176 (67) | 55 (76) |
| Not reported | 8 (2) | 3 (1) | 4 (<1) | 2 (<1) | 1 (<1) | — | — |
| Performance score | |||||||
| 90-100 | 297 (62) | 181 (66) | 340 (66) | 193 (48) | 142 (54) | 95 (48) | 43 (60) |
| ≤80 | 169 (36) | 88 (32) | 178 (34) | 207 (51) | 120 (46) | 101 (51) | 29 (40) |
| Not reported | 11 (2) | 7 (2) | — | 5 (1) | 1 (<1) | 2 (1) | — |
| HCT-CI | |||||||
| 0-2 | 248 (52) | 148 (54) | 269 (52) | 180 (44) | 100 (38) | 92 (46) | 35 (49) |
| ≥3 | 229 (48) | 128 (46) | 247 (48) | 225 (56) | 160 (61) | 103 (52) | 37 (51) |
| Not reported | — | — | 2 (<1) | — | 3 (1) | 3 (2) | — |
| Disease | |||||||
| AML | 285 (60) | 161 (58) | 362 (70) | 178 (44) | 142 (54) | 96 (48) | 34 (47) |
| MDS | 192 (40) | 115 (42) | 156 (30) | 227 (56) | 121 (46) | 102 (52) | 38 (53) |
| Disease status* | |||||||
| CR1 | 220 (46) | 113 (41) | 264 (51) | 146 (36) | 111 (42) | 78 (39) | 25 (35) |
| CR2 | 65 (13) | 48 (17) | 98 (19) | 32 (7) | 31 (11) | 18 (9) | 9 (13) |
| RA/RARS | 14 (3) | 6 (1) | 18 (3) | 15 (3) | 11 (5) | 11 (6) | 5 (7) |
| RCMD | 51 (11) | 29 (11) | 26 (5) | 62 (15) | 33 (13) | 19 (10) | 5 (7) |
| 5q− syndrome | 1 (<1) | 1 (<1) | 2 (<1) | 4 (<1) | — | 1 (<1) | — |
| RAEB-1/RAEB-2 | 126 (27) | 79 (28) | 110 (21) | 146 (36) | 77 (29) | 71 (36) | 28 (39) |
| Cytogenetic risk | |||||||
| Favorable | 22 (5) | 16 (6) | 30 (6) | 10 (3) | 13 (5) | 4 (2) | 2 (3) |
| Intermediate | 353 (74) | 180 (65) | 388 (75) | 290 (72) | 171 (65) | 140 (71) | 52 (72) |
| Unfavorable | 87 (18) | 71 (26) | 75 (14) | 83 (20) | 64 (24) | 44 (22) | 15 (21) |
| Not reported | 15 (3) | 9 (3) | 25 (5) | 22 (5) | 15 (6) | 10 (5) | 3 (4) |
| Disease risk index | |||||||
| Low | 22 (5) | 16 (6) | 30 (6) | 10 (3) | 13 (5) | 4 (2) | 2 (3) |
| Intermediate | 273 (57) | 144 (52) | 315 (61) | 191 (47) | 130 (49) | 97 (49) | 36 (50) |
| High | 166 (35) | 106 (38) | 146 (28) | 178 (44) | 105 (40) | 86 (44) | 31 (43) |
| Not reported | 16 (3) | 10 (4) | 27 (5) | 26 (6) | 15 (6) | 11 (5) | 3 (4) |
| Donor | |||||||
| Matched sibling | 229 (48) | 22 (8) | 228 (44) | 177 (44) | 37 (14) | 84 (42) | 4 (6) |
| Unrelated donor: matched | 223 (47) | 204 (74) | 256 (49) | 192 (47) | 199 (76) | 91 (46) | 39 (54) |
| Unrelated donor: mismatched | 25 (5) | 50 (18) | 34 (7) | 36 (9) | 27 (10) | 23 (12) | 29 (40) |
| Graft | |||||||
| Bone marrow | 50 (10) | 49 (18) | 83 (16) | 8 (2) | 17 (6) | 25 (13) | 21 (29) |
| Peripheral blood | 427 (90) | 227 (82) | 435 (84) | 397 (98) | 246 (94) | 173 (87) | 51 (71) |
| Donor/recipient sex match | |||||||
| Female/female | 76 (16) | 39 (14) | 99 (19) | 63 (16) | 30 (11) | 37 (19) | 15 (21) |
| Female/male | 88 (18) | 48 (18) | 96 (18) | 75 (18) | 29 (11) | 36 (18) | 11 (15) |
| Male/female | 137 (29) | 81 (29) | 153 (30) | 85 (21) | 76 (29) | 46 (23) | 14 (19) |
| Male/male | 176 (37) | 108 (39) | 170 (33) | 182 (45) | 128 (49) | 79 (40) | 32 (44) |
| GVHD prophylaxis | |||||||
| Tac + MMF | 106 (22) | 61 (22) | 40 (8) | 49 (12) | 119 (45) | 42 (21) | 13 (18) |
| Tac + MTX | 353 (74) | 203 (74) | 418 (81) | 338 (84) | 126 (48) | 125 (63) | 44 (61) |
| CsA + MMF | 11 (3) | 6 (2) | 22 (4) | 8 (2) | 14 (5) | 11 (6) | 5 (7) |
| CsA + MMF | 7 (1) | 6 (2) | 38 (7) | 10 (2) | 4 (2) | 20 (10) | 10 (14) |
| Transplant period | |||||||
| 2009-2011 | 221 (46) | 141 (51) | 276 (53) | 102 (25) | 121 (46) | 52 (26) | 15 (21) |
| 2012-2014 | 256 (54) | 135 (49) | 242 (47) | 303 (75) | 142 (54) | 146 (74) | 57 (79) |
| . | Flu/Bu4 . | Flu/Bu4 + ATG . | Bu4/Cy . | Flu/Bu2 . | Flu/Bu2 + ATG . | Flu/Mel . | Flu/Mel + ATG . |
|---|---|---|---|---|---|---|---|
| Patients, n | 477 | 276 | 518 | 405 | 263 | 198 | 72 |
| Median age, y | 56 | 56 | 51 | 63 | 63 | 63 | 64 |
| Age, y | |||||||
| 18-39 | 72 (15) | 54 (20) | 113 (22) | 14 (4) | 13 (5) | 6 (3) | 6 (8) |
| 40-59 | 255 (54) | 130 (47) | 355 (68) | 112 (27) | 78 (30) | 52 (26) | 17 (24) |
| ≥60 | 150 (31) | 92 (33) | 50 (10) | 279 (69) | 172 (65) | 140 (71) | 49 (68) |
| Sex, male | 264 (55) | 156 (57) | 266 (51) | 257 (63) | 115 (58) | 157 (60) | 43 (60) |
| CMV serostatus | |||||||
| Negative | 179 (37) | 100 (36) | 211 (41) | 169 (42) | 53 (27) | 87 (33) | 17 (24) |
| Positive | 290 (61) | 173 (63) | 303 (58) | 234 (58) | 144 (73) | 176 (67) | 55 (76) |
| Not reported | 8 (2) | 3 (1) | 4 (<1) | 2 (<1) | 1 (<1) | — | — |
| Performance score | |||||||
| 90-100 | 297 (62) | 181 (66) | 340 (66) | 193 (48) | 142 (54) | 95 (48) | 43 (60) |
| ≤80 | 169 (36) | 88 (32) | 178 (34) | 207 (51) | 120 (46) | 101 (51) | 29 (40) |
| Not reported | 11 (2) | 7 (2) | — | 5 (1) | 1 (<1) | 2 (1) | — |
| HCT-CI | |||||||
| 0-2 | 248 (52) | 148 (54) | 269 (52) | 180 (44) | 100 (38) | 92 (46) | 35 (49) |
| ≥3 | 229 (48) | 128 (46) | 247 (48) | 225 (56) | 160 (61) | 103 (52) | 37 (51) |
| Not reported | — | — | 2 (<1) | — | 3 (1) | 3 (2) | — |
| Disease | |||||||
| AML | 285 (60) | 161 (58) | 362 (70) | 178 (44) | 142 (54) | 96 (48) | 34 (47) |
| MDS | 192 (40) | 115 (42) | 156 (30) | 227 (56) | 121 (46) | 102 (52) | 38 (53) |
| Disease status* | |||||||
| CR1 | 220 (46) | 113 (41) | 264 (51) | 146 (36) | 111 (42) | 78 (39) | 25 (35) |
| CR2 | 65 (13) | 48 (17) | 98 (19) | 32 (7) | 31 (11) | 18 (9) | 9 (13) |
| RA/RARS | 14 (3) | 6 (1) | 18 (3) | 15 (3) | 11 (5) | 11 (6) | 5 (7) |
| RCMD | 51 (11) | 29 (11) | 26 (5) | 62 (15) | 33 (13) | 19 (10) | 5 (7) |
| 5q− syndrome | 1 (<1) | 1 (<1) | 2 (<1) | 4 (<1) | — | 1 (<1) | — |
| RAEB-1/RAEB-2 | 126 (27) | 79 (28) | 110 (21) | 146 (36) | 77 (29) | 71 (36) | 28 (39) |
| Cytogenetic risk | |||||||
| Favorable | 22 (5) | 16 (6) | 30 (6) | 10 (3) | 13 (5) | 4 (2) | 2 (3) |
| Intermediate | 353 (74) | 180 (65) | 388 (75) | 290 (72) | 171 (65) | 140 (71) | 52 (72) |
| Unfavorable | 87 (18) | 71 (26) | 75 (14) | 83 (20) | 64 (24) | 44 (22) | 15 (21) |
| Not reported | 15 (3) | 9 (3) | 25 (5) | 22 (5) | 15 (6) | 10 (5) | 3 (4) |
| Disease risk index | |||||||
| Low | 22 (5) | 16 (6) | 30 (6) | 10 (3) | 13 (5) | 4 (2) | 2 (3) |
| Intermediate | 273 (57) | 144 (52) | 315 (61) | 191 (47) | 130 (49) | 97 (49) | 36 (50) |
| High | 166 (35) | 106 (38) | 146 (28) | 178 (44) | 105 (40) | 86 (44) | 31 (43) |
| Not reported | 16 (3) | 10 (4) | 27 (5) | 26 (6) | 15 (6) | 11 (5) | 3 (4) |
| Donor | |||||||
| Matched sibling | 229 (48) | 22 (8) | 228 (44) | 177 (44) | 37 (14) | 84 (42) | 4 (6) |
| Unrelated donor: matched | 223 (47) | 204 (74) | 256 (49) | 192 (47) | 199 (76) | 91 (46) | 39 (54) |
| Unrelated donor: mismatched | 25 (5) | 50 (18) | 34 (7) | 36 (9) | 27 (10) | 23 (12) | 29 (40) |
| Graft | |||||||
| Bone marrow | 50 (10) | 49 (18) | 83 (16) | 8 (2) | 17 (6) | 25 (13) | 21 (29) |
| Peripheral blood | 427 (90) | 227 (82) | 435 (84) | 397 (98) | 246 (94) | 173 (87) | 51 (71) |
| Donor/recipient sex match | |||||||
| Female/female | 76 (16) | 39 (14) | 99 (19) | 63 (16) | 30 (11) | 37 (19) | 15 (21) |
| Female/male | 88 (18) | 48 (18) | 96 (18) | 75 (18) | 29 (11) | 36 (18) | 11 (15) |
| Male/female | 137 (29) | 81 (29) | 153 (30) | 85 (21) | 76 (29) | 46 (23) | 14 (19) |
| Male/male | 176 (37) | 108 (39) | 170 (33) | 182 (45) | 128 (49) | 79 (40) | 32 (44) |
| GVHD prophylaxis | |||||||
| Tac + MMF | 106 (22) | 61 (22) | 40 (8) | 49 (12) | 119 (45) | 42 (21) | 13 (18) |
| Tac + MTX | 353 (74) | 203 (74) | 418 (81) | 338 (84) | 126 (48) | 125 (63) | 44 (61) |
| CsA + MMF | 11 (3) | 6 (2) | 22 (4) | 8 (2) | 14 (5) | 11 (6) | 5 (7) |
| CsA + MMF | 7 (1) | 6 (2) | 38 (7) | 10 (2) | 4 (2) | 20 (10) | 10 (14) |
| Transplant period | |||||||
| 2009-2011 | 221 (46) | 141 (51) | 276 (53) | 102 (25) | 121 (46) | 52 (26) | 15 (21) |
| 2012-2014 | 256 (54) | 135 (49) | 242 (47) | 303 (75) | 142 (54) | 146 (74) | 57 (79) |
With the exception of the number of patients and median age, all data are n (%).
—, null; CR, complete remission; CsA, cyclosporine; MMF, mycophenolate; MTX, methotrexate; RAEB, RA with excess blasts; RARS, RA with ringed sideroblast; RCMD, RA with multilineage dysplasia; Tac, tacrolimus.
World Health Organization 2016 MDS terminology: RA, MDS-SLD (MDS with single lineage dysplasia); RARS, MDS-RS-SLD (MDS with ringed sideroblasts and single lineage dysplasia); RCMD, MDS-MLD (MDS with multilineage dysplasia); RAEB-1/2, MDS-EB1/2 (MDS with excess blasts); 5q− syndrome, MDS with isolated del(5q).